Creating a new generation of small molecule protease inhibitors

Key Publications


Simao F, Ustunkaya T, Clermont AC and Feener EP Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke. Blood. 2017.

Clermont A, Murugesan N, Zhou Q, Kita T, Robson PA, Rushbrooke LJ, Evans DM, Aiello LP, Feener EP. Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening. Invest Ophthalmol Vis Sci. 2016;57:2390-9.

Kita T, Clermont AC, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T, Aiello LP, Feener EP. Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. Diabetes. 2015;64:3588-99.

Liu J, Clermont AC, Gao BB, Feener EP. Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein. Invest Ophthalmol Vis Sci. 2013;54:1086-1094.

Clermont A, Chilcote TJ, Kita T, Liu J, Riva P, Sinha S and Feener EP. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes. 2011;60(5):1590-8.

Liu J, Gao B-B, Clermont AC, Blair P, Chilcote TJ, Sinha S, Flaumenhaft R and Feener EP. Hyperglycemia induced cerebral hematoma expansion is mediated by plasma kallikrein. Nature Medicine. 2011;17:206-10.

Feener EP. Plasma kallikrein and diabetic macular edema. Curr. Diab. Rep. 2010 Aug;10(4):270-5.

Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell S-E and Feener EP. Plasma kallikrein mediates angiotensin AT1 receptor stimulated retinal vascular permeability. Hypertension 2009;53:175-81.

Phipps JA and Feener EP. The kallikrein-kinin system in diabetic retinopathy: Lessons for the kidney. Kidney Int., 2008;73(10):1114-9.


Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP and Feener EP. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nature Medicine. 2007;13:181-8.